CXCL16 and ankylosing spondylitis: A prior study has demonstrated that recombinant tumor necrosis factor receptor: Fc fusion protein (rhTNFR: Fc) was able to mitigate inflammation in patients with ankylosing spondylitis by inhibiting the Cxcl16/Cxcr6 pathway 30.